Navigation Links
MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
Date:1/18/2011

WARREN, N.J., Jan. 18, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, filed an amended patent infringement and false marking lawsuit today against BioDelivery Sciences International, Inc. (NASDAQ: BDSI; "BDSI"), MEDA Pharmaceuticals Inc. ("MEDA"), and Aveva Drug Delivery Systems, Inc. ("Aveva") in the United States District Court for the District of New Jersey.

MonoSol Rx's complaint asserts that BDSI, MEDA, and Aveva's manufacture, marketing, and sale of the Onsolis™ film products infringe MonoSol Rx's United States Patent No. 7,824,588 related to methods of making drug-containing films.  As one of the leaders in the development and commercialization of film pharmaceutical and over-the-counter drug products, MonoSol Rx has an extensive technology patent portfolio.

MonoSol Rx filed its patent infringement claim against these defendants initially in November, 2010.  Today's amended complaint adds an additional false marking claim with respect to U.S. Patent No. 5,800,832.

MonoSol Rx is represented in the action by Howrey LLP.

About MonoSol Rx MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.
For press releases and other company information visit www.monosolrx.com Contacts:MonoSol RxKeith Kendall, Executive Vice President(732) 564-5000The Ruth Group
(on behalf of MonoSol Rx)Jason Rando (media)Tel: +1 (646) 536-7025jrando@theruthgroup.com  Sara Pellegrino (investors)Tel: +1 (646) 536-7002spellegrino@theruthgroup.com  
'/>"/>

SOURCE MonoSol Rx, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
4. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
5. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
6. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
7. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. ERT Files Shelf Registration Statement
11. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):